Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...